Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Gains from Sales and Divestitures (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Gains from Sales and Divestitures data on record, last reported at $112159.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 697.04% year-over-year to $112159.0; the TTM value through Sep 2025 reached $112159.0, up 697.04%, while the annual FY2024 figure was $14696.0, 85.57% down from the prior year.
  • Gains from Sales and Divestitures reached $112159.0 in Q3 2025 per GLUE's latest filing, roughly flat from $112159.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $112159.0 in Q2 2025 and bottomed at $4691.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 3 years is $56464.6, with a median of $49284.5 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: tumbled 85.87% in 2024, then soared 1095.6% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $101855.0 in 2023, then plummeted by 85.57% to $14696.0 in 2024, then surged by 663.19% to $112159.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $112159.0 in Q3 2025, $112159.0 in Q2 2025, and $14696.0 in Q4 2024.